Villaseca P, Arteaga E, Campusano C, López J M, Rojas A, Nazar G, O'Brien A
Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile.
Rev Med Chil. 1996 Dec;124(12):1439-46.
The effects of different therapies on bone loss rate can be measured using biochemical markers of bone resorption such as urinary hydroxyproline.
To study the effects of hormone replacement therapy on urinary hydroxyproline in postmenopausal women.
Eighty three postmenopausal women without hormone replacement therapy, 54 postmenopausal women receiving hormone replacement therapy and 16 premenopausal women (considered as the control group) were studied. Hydroxyproline was measured in an early morning urine sample, after one day of diet without meat or gelatin.
Urinary hydroxyproline in premenopausal women was 33.7 +/- 7.9 mg/g creatinine. The figure for postmenopausal women with hormonal replacement therapy was 33.7 +/- 5.9 mg/g creatinine. Postmenopausal women without replacement therapy had an urinary hydroxyproline of 47.4 +/- 8.5 mg/g creatinine, significantly higher than that of premenopausal and supplemented women. In 21 postmenopausal women, hydroxyproline was measured before and after three months of replacement therapy, values decreased 35.5 +/- 11% in this period and there was a direct correlation between initial values and the degree of reduction (r = 0.69, p < 0.001).
Postmenopausal women receiving hormone replacement therapy have a urinary hydroxyproline excretion similar to that of premenopausal women.
